Bristol Myers Squibb’s Cobenfy failed to outdistance a placebo in a Phase 3 test that evaluated the drug as an adjunct to antipsychotics in schizophrenia patients. Last September, the FDA approved Cobenfy as a standalone schizophrenia treatment.
The post Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics appeared first on MedCity News.
